Chronic obstructive pulmonary disease Trials in Frankfurt, Germany
Conditions / Chronic obstructive pulmonary disease / Frankfurt, Germany
Research into Chronic obstructive pulmonary disease spans multiple therapeutic approaches and trial phases.
24 total trials for this combination
Showing top 10 of 24 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT01120691 | Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations | COMPLETED | PHASE3 |
| NCT05572333 | Clinical Trial to Investigate the Safety and Tolerability of EP395 in Patients With COPD | COMPLETED | PHASE2 |
| NCT01867762 | An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease | COMPLETED | PHASE2 |
| NCT06208306 | A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT00393458 | Efficacy, Safety, and Tolerability of Once Daily Indacaterol in Chronic Obstructive Pulmonary Disease (COPD) Using Formoterol Twice Daily as Active Control | COMPLETED | PHASE3 |
| NCT02796677 | AMPLIFY - D6571C00001 Duaklir USA Phase III Study | COMPLETED | PHASE3 |
| NCT00845728 | Exacerbation Study | COMPLETED | PHASE3 |
| NCT05878769 | A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) | RECRUITING | PHASE3 |
| NCT00206167 | A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and 2 x 80/4.5 μg Bid With Formoterol Turbuhaler® 2 x 4.5 μg Bid and Placebo in Patients With COPD | COMPLETED | PHASE3 |
| NCT04636801 | A 52-week, Placebo-controlled Study to Evaluate the Efficacy and Safety of 2 Doses of CHF6001 DPI (Tanimilast), as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis (PILASTER) | TERMINATED | PHASE3 |